Stocks Most Shunned by Hedge Funds and Mutual Funds

Seeking Alpha04:00

J&J Says Rybrevant Combo Bests AstraZeneca's Tagrisso in Type of Lung Cancer

Seeking AlphaJun 1 05:53

Gilead's Trodelvy Falls Short in Significantly Improving Overall Survival in NSCLC

Seeking AlphaMay 31 23:06

Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer

On Thursday, Gilead Sciences Inc (NASDAQ:GILD) announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).The TROPiCS-04 study e

BenzingaMay 31 21:27

Gilead Sciences To Present EVOKE-01 Study Results In Metastatic NSCLC At An Oral Session At ASCO 2024

– Simultaneously Published by the Journal of Clinical Oncology –Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an or

BenzingaMay 31 20:16

Gilead Shares Are Trading Lower After the Company's Phase 3 TROPiCS-04 Study Missed Its Primary Endpoint of Overall Survival.

Gilead Shares Are Trading Lower After the Company's Phase 3 TROPiCS-04 Study Missed Its Primary Endpoint of Overall Survival.

BenzingaMay 31 04:46